Brief: SARS-CoV-2 Spike Protein Licensed By Oragenics From The NIH Demonstrates Protective Immunity In Mice
02/02/2021 13:06
Feb 2 (Reuters) - Oragenics Inc OGEN.A :
* SARS-COV-2 SPIKE PROTEIN LICENSED BY ORAGENICS FROM THE
NIH
DEMONSTRATES PROTECTIVE IMMUNITY IN MICE
Source text for Eikon: ID:nBw8rM21pa
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing